Wednesday, November 11, 2026

Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source documentYahoo Finance· November 8, 2026

Don’t Miss Out: 5 Stocks Getting Major Upgrades From Top Analysts

View original at finance.yahoo.com

Don’t Miss Out: 5 Stocks Getting Major Upgrades From Top Analysts Wall Street ended a punishing week on Friday with a partial recovery. The Nasdaq Composite rose 1.09% to 24,579.42 and the S&P 500 gained 0.31% to 7,376.86, while the Dow Jones Industrial Average slipped 0.46% on November 6…

Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

Data points we hold from this source

Federal Reserve · december hike probability

78 percent

What we know · the intelligence behind this page

Live from the substrate

What we're seeing

Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring

A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.

Our read on the data ›

Signals we're tracking

EPKINLY Regulatory-Clinical Success Cascade

High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.

Patterns we're watching ›

Where sources disagree

Ford Motor Company

Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.

We flag conflicts openly ›

Recently verified

✓ Checked against the original source

4,995

facts traced to their source — and we flag the ones that don't hold up.

101 entities tracked4,995 facts checked against source5,564 source documents archived

Query this data → isubstrate.com